Atreca jumps on agreement to develop malaria drug

Atreca

21/10/2021 14:18

** Biotech company's shares  BCEL.O  up 5.7% at $5.54
    ** Company enters agreement with the Bill & Melinda Gates
Medical Research Institute to develop monoclonal antibody for
prevention of malaria
    ** BCEL will market the drug in the U.S., Europe and parts
of Asia post approval  urn:newsml:reuters.com:*:nGNX3DjS5M
    ** Bill & Melinda Gates Medical Research Institute will lead
development of the drug and commercialize it in GAVI-eligible
countries where malaria is prevalent
    ** Up to Wednesday's close, BCEL stock down about 68% YTD

 (Reporting by Leroy Leo in Bengaluru)
 ((Leroy.Dsouza@thomsonreuters.com))